BIONIK Laboratories Corp announces it has entered into a purchase order with Clinique Les Trois Soleils, a rehabilitation facility in Boissise-le-Roi, France, for the company’s InMotion Arm robot.
This purchase marks the fourth InMotion robotic system the company has bought. Clinique Les Trois Soleils already owns three units of earlier models of the InMotion Arm and Wrist robotic systems, according to BIONIK Labs.
“We are thrilled to partner with BIONIK once again to provide innovative technology and therapeutic solutions to our patients. BIONIK’s InMotion Arm system has empowered our patients to succeed in their rehabilitation treatment, providing improved outcomes for many,” says Paul Gobin, chief executive officer of Clinique Les Trois Soleils, in a media release.
Clinique Les Trois Soleils is reportedly the first private for-profit rehabilitation center in the Île-de-France region to develop a neurological arm rehabilitation robotics center, with 68 inpatient beds for patients undergoing rehabilitation following stroke, spinal cord injury, multiple sclerosis, or other neurological conditions.
Clinique Les Trois Soleils has also published many key studies with the InMotion robotic systems and continues to conduct clinical trials with patients following stroke. Studies led by Dr Christophe Duret and his colleagues have investigated the effectiveness of robotic therapy when combined with, or compared to, usual care, and demonstrated the beneficial impact of robotics on the motor recovery process.
“We are excited to continue our terrific collaboration with Clinique Les Trois Soleils for another InMotion Arm robotic system,” states Dr Eric Dusseux, chief executive officer and director of BIONIK Laboratories, the release continues.
“While developing new business pipelines is a priority, we are pleased to serve current customers through the purchase of additional units. We believe that the continued selection of BIONIK’s InMotion Arm by Clinique Les Trois Soleils validates to the European market that our technology is best positioned to provide optimal patient outcomes and become an integral part of a neurological therapy regimen.”
[Source(s): BIONIK Laboratories Corp, PR Newswire]
